E
Elliot M. Frohman
Researcher at University of Texas at Austin
Publications - 314
Citations - 21300
Elliot M. Frohman is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Multiple sclerosis & Optic neuritis. The author has an hindex of 71, co-authored 300 publications receiving 19508 citations. Previous affiliations of Elliot M. Frohman include University of California, Irvine & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Multiple Sclerosis — The Plaque and Its Pathogenesis
TL;DR: This review focuses on the current knowledge of the pathogenesis of the inflammatory and neurodegenerative elements of the multiple sclerosis plaque.
Journal ArticleDOI
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Douglas S. Goodin,Elliot M. Frohman,G. P. Garmany,J. Halper,William Likosky,Fred D. Lublin,D. H. Silberberg,W. H. Stuart,S. van den Noort +8 more
TL;DR: Clinical trials study patients for only short periods of time (2 or 3 years) and, therefore, use only short-term outcome measures to assess efficacy, and evaluation of the relative effectiveness of different therapies requires consideration of which outcome measure or measures are relevant to the goals of therapy.
Journal ArticleDOI
Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Jennifer B. Fisher,Dina A. Jacobs,Clyde E. Markowitz,Steven L. Galetta,Nicholas J. Volpe,M. Ligia Nano-Schiavi,Monika Baier,Elliot M. Frohman,Heather Winslow,Teresa C. Frohman,Peter A. Calabresi,Maureen G. Maguire,Gary Cutter,Laura J. Balcer +13 more
TL;DR: Scores for low-contrast letter acuity and contrast sensitivity correlate well with RNFL thickness as a structural biomarker, supporting validity for these visual function tests as secondary clinical outcome measures for MS trials.
Journal ArticleDOI
Quantitative sensory testing: Report of the therapeutics and technology assessment subcommittee of the American academy of neurology
Michael E. Shy,Elliot M. Frohman,Yuen T. So,Joseph C. Arezzo,David R. Cornblath,M. J. Giuliani,John C. Kincaid,J. L. Ochoa,Gareth Parry,Louis H. Weimer +9 more
TL;DR: QST is a potentially useful tool for measuring sensory impairment for clinical and research studies, however, it should not be the sole criteria used to diagnose pathology and is not currently useful for the purpose of resolving medicolegal matters.
Journal ArticleDOI
Immune surveillance in multiple sclerosis patients treated with natalizumab
Olaf Stüve,Olaf Stüve,Christina M. Marra,Keith R. Jerome,Keith R. Jerome,Keith R. Jerome,Linda S. Cook,Linda S. Cook,Linda S. Cook,Petra D. Cravens,Sabine Cepok,Elliot M. Frohman,J. Theodore Phillips,Gabriele Arendt,Bernhard Hemmer,Nancy L. Monson,Michael K. Racke +16 more
TL;DR: Whether natalizumab, an antibody against very late activating antigen (VLA)‐4, interferes with central nervous system immune surveillance as assessed by leukocyte cell numbers and cellular phenotypes in cerebrospinal fluid (CSF) and peripheral blood is tested.